Evidence map›Paper›PMID 37436169›Full record

ArticleMicrobiology spectrum2023

Selective Pressure by Rifampicin Modulates Mutation Rates and Evolutionary Trajectories of Mycobacterial Genomes.

E Cebrián-Sastre, A Chiner-Oms, R Torres-Pérez, I Comas, J C Oliveros, J Blázquez, A Castañeda-García

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Pyocyanin produced byAntimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

E Cebrián-SastreDepartamento de Biotecnología Microbiana, Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain.ORCID 0000-0002-5594-387X
A Chiner-OmsInstituto de Biomedicina de Valencia (IBV), CSIC, Valencia, Spain.
R Torres-PérezServicio de Bioinformática para Genómica y Proteómica. Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain.
I ComasInstituto de Biomedicina de Valencia (IBV), CSIC, Valencia, Spain.ORCID 0000-0001-5504-9408
J C OliverosServicio de Bioinformática para Genómica y Proteómica. Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain.
J BlázquezDepartamento de Biotecnología Microbiana, Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain.
A Castañeda-GarcíaDepartamento de Biotecnología Microbiana, Centro Nacional de Biotecnología (CNB), CSIC, Madrid, Spain.
Centro Nacional de Biotecnología · ESInstituto de Biomedicina de Valencia · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to the frontline antibiotic rifampicin constitutes a challenge to the treatment and control of tuberculosis. Here, we analyzed the mutational landscape of Mycobacterium smegmatis during long-term evolution with increasing concentrations of rifampicin, using a mutation accumulation assay combined with whole-genome sequencing. Antibiotic treatment enhanced the acquisition of mutations, doubling the genome-wide mutation rate of the wild-type cells. While antibiotic exposure led to extinction of almost all wild-type lines, the hypermutable phenotype of the Δ

Indexed as

Mycobacterium tuberculosisTuberculosisAnti-Bacterial AgentsAntitubercular AgentsBacterial ProteinsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationMutation RateRifampinAnti-Bacterial AgentsAntitubercular AgentsBacterial ProteinsRifampinantibiotic resistanceDNA repairdrug resistance evolutionevolutionexperimental evolutionmutationmutation accumulationMycobacteriumMycobacterium smegmatisrifampicin

Identifiers

PMID37436169
PMCPMC10433840
OpenAlexW4383998418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.